ACR Meeting Abstracts

ACR Meeting Abstracts

Session » 3S110 ACR Abstract: SLE–Clinical I: Clinical Trials (970–975)

Date: Sunday, October 21, 2018

Time: 4:30PM-6:00PM

Meeting: 2018 ACR/ARHP Annual Meeting

Abstract Number: 970
Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Abstract Number: 971
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept or Placebo on Standard of Care in Patients with Active Class III or IV Lupus Nephritis
Abstract Number: 972
An Anti-CD28 Domain Antibody, Lulizumab, in Systemic Lupus Erythematosus: Results of a Phase II Study
Abstract Number: 973
Low-Dose IL-2 Combined with Rapamycin Efficiently Promoted Disease Remission and Recovered the Balance of Th17/Regulatory T Cells in Patients with Refractory Systemic Lupus Erythematosus
Abstract Number: 974
Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis: A Prospective, Multicenter, Randomized, Open-Label Clinical Trial
Abstract Number: 975
Alteration of Vascular Inflammatory Markers in SLE By Anifrolumab in the Phase IIb Muse Study

« View all sessions from this meeting